weazelboy
4 days ago
Gwinner- I hate to break it to you, but nothing about this company can currently be taken seriously...including the price action. It's all fictitious games.
Based on current price, simply put a large bid/ask below and above, respectively, that is unlikely to get hit given the volume is so putrid...therein creating the mirage that there is a set range/market. Reality is, it's all shenanigans. Case in point this morning, 8.15 offer...yet someone puts a bid at 8.10 rather than just hitting the offer. It's a measly $5.00 difference for the 100 share lot showing, so if that person(s) were serious...hitting the offer versus waiting on the bid is immaterial.
Unless/until we see real, consistent volume for several days...anything else means nada.
Again, same as it ever was...
weazelboy
2 weeks ago
At this point, you are correct...that is literally the only way they can raise money moving forward if needed (ridiculously cheap shares via PP). However, even that needs some type of promise of an exit for the purchaser(s) to get "something" out of it, even if by means of selling those acquired shares...as otherwise it's just pissing money away to the new buyer when you have $1-$2.50 spreads and zero consistent volume.
This all feels like one last ditch effort for the grand slam, sale of company to me. While I know Amigo mentions the possibilities of other verticals (and they certainly do have them)...I'm just not sure the folks in charge wanna hassle or stick around for that given how long this has been. Seems like a show me the money, here's the keys to the car and be done situation here. JMO. We'll see how it shapes up.
Ideally we'll see consistent volume "suddenly" appear at some point over the next month to give an opportunity to position, but given the last 3-4 months...not counting on it. I still have my pittance of shares from last December for now.
Amigo Mike
3 weeks ago
Agreed,
Cannot build a position with the spread as wide as it is and the movement either way if someone sniffs it.
Happy to see it funded by a major pharma ..... but I'd like to know if it is the same pharma as before .... or is it another pharma getting into the fray ..... and if it is another pharma ..... is there a competition brewing .... or did other pharma drop from the picture. I would think that to be a valuable piece of info.
My impression is the original pharma .... who actually botched the original test ..... was continuing to talk to ZIVO all this time. So is it still them or someone else??? Can't tell from the PR. The original pharma I would think has all the data. This test is a little different and some different variations that I think are certainly worthy of testing but at same time, the data from prior tests is what it is ... and was performed under real world 42 day grow cycle conditions.
Personally I am ALL FOR COMPETITION. I have noted here before .... if I were Payne, I would have sent data to ALL the major pharmas with coccidiosis treatments and I would have done articles or interviews with animal groups pushing to have antibiotics removed from animal therapeutics. Enough dicking around. =)
But at same time I do realize ZIVO may be in a delicate position ... but at some point, if you think you have the breakthrough that you do ...... you need to turn up the gas and try to make best deal possible to commercialize. If all the eggs are in a single pharma's basket, then they get to dictate ...... If everyone gets the data and a chance to review and decide ...... then everyone knows the deal when everything shakes out if ZIVO has da goods or not and ZIVO can choose the best option to move forward. And if the other pharmas don't step up and have their products adversely impacted ... they had their shot at it.
In my book, chickens is only the tip of the iceberg. ZIVO toss in some additional data on other potential verticals, and a major pharma could get those things done much faster. And who knows, maybe one of them would just buy the company. Like glucosamine and animal joint health is a layup. Glucosamine I don't think really does much of anything, ZIVO on the other hand ..... they could do those tests easy. And animal joint supplement blows the rest away.
So I agree, it is time for major pharma to $hit or get off the pot with this. IMO ZIVO needs to turn up the gas bigtime. And at end of this time, need an offer on the table.
Amigo Mike
Amigo Mike
3 weeks ago
Major Global Animal Health Company Launches 42-Day Confirmatory Study with ZIVO Bioscience’s Coccidiosis Treatment in Broiler Chickens
July 08 2024 - 8:00AM
Business Wire
ZIVO Bioscience, Inc. (NASDAQ: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day confirmatory study targeting coccidiosis in collaboration with a major global animal health company.
This new study aims to further validate the efficacy of ZIVO’s non-antibiotic, immune-modulating product designed for the prevention and treatment of coccidiosis in broiler chickens. Building upon the positive outcomes of previous trials, this study replicates real-world conditions to ensure the product's effectiveness in commercial poultry production environments.
“We are delighted to support a global leader in animal health as they perform this confirmatory study, which holds potential to accelerate commercialization of our innovative treatment. Coccidiosis costs the poultry industry more than $10 billion annually, and traditional treatments rely heavily on antibiotics and ionophores that have not seen significant innovation in over six decades,” said John Payne, Chairman and CEO of ZIVO Bioscience.
“This 42-day study is a significant step forward in our mission to provide sustainable, antibiotic-free solutions for the poultry industry. Our product represents a groundbreaking alternative designed to boost the immune response of broiler chickens without the adverse effects associated with legacy treatments. We are optimistic the results of this study will further support its market readiness,” he added.
Funded by the major animal health company, the study focuses on the overall health and productivity of the birds under typical industry conditions, and compares administration of ZIVO’s product versus an ionophore-based treatment and versus an ionophore-based treatment combined with ZIVO’s product. The study also compares the benefits of ZIVO’s product combined with coccidiosis vaccine versus administration without the vaccine. Results from the study are expected to be available in September.
About Coccidiosis
Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance and increased mortality in poultry. This disease represents a significant economic challenge for the global poultry industry, as indicated by a 2020 study that estimated annual costs ranging from $10 billion to $17 billioni. Products for treating coccidiosis are mostly antibiotic- or ionophore-based, and no significant new commercial technology has been introduced in the past 60 years. The global poultry industry spends more than $1.5 billion annually on coccidiosis control, primarily using decades-old compounds that industry and consumers alike want to replace due to the risks of developing drug resistance. Coccidiosis is a common disease for chickens, especially among young chicks, and can be fatal or result in compromised digestion.
About ZIVO Bioscience
ZIVO Bioscience is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.